Key Takeaways
- Revenue surged 50% YoY, margin hit 18%: Operating revenue grew 50.15% YoY and 26.22% QoQ, while EBITDA margin expanded 1,256 bps YoY to 18.02%, driven by product mix optimization and operating leverage.
- CDMO is scaling fast, led by one molecule: Contract manufacturing revenue jumped to 27% of sales, with the Atorvastatin + Ezetimibe molecule alone more than doubling QoQ from ~₹25 crore to ~₹58 crore.
- Own-brand exports are the structural story: Own brands now contribute 55.75% of sales and 69% of exports, with management deliberately shifting toward higher-margin, fully controlled products in new geographies.
- The balance sheet is net debt-free, and a stake sale looms: The company holds tag-along rights in Synthimed Labs, where a partial stake monetization may occur in coming quarters if valuations are good, as two Hyderabad pharma companies conduct diligence.
- What to watch next quarter: Whether the Q3 margin reaches the promised 19–20%, the pace of Ibuprofen sachet ramp toward the ₹20 crore quarterly run-rate, and any update on the Synthimed stake sale.
Revenue Growth & Drivers
- Broad-based top-line acceleration: Q2 FY27 operating revenue grew 50.15% YoY and 26.22% QoQ, with H1 FY27 revenue up 35.79% YoY to ₹420.97 crore. Management stated it feels "very comfortable" achieving the full-year guidance of more than 50% revenue growth.
- Export engine dominates: Exports contributed 82.7% of total sales in Q2, a ratio management expects to hold around 80% going forward. Growth is coming from both existing GCC, Central Asian and African markets and newly opened territories.
- Own-brand mix is deliberately rising: Own branded products reached 68% of export revenue mix in Q2, up from prior periods, driven by a strategy to register more own molecules in new markets where margins are higher and the company retains full product and market control.
- CDMO molecule concentration: The Atorvastatin + Ezetimibe molecule alone contributed ~₹58 crore in Q2, up from ~₹25 crore in Q1, making it the single largest CDMO growth driver. Ibuprofen sachet revenue was ~₹15–16 crore in H1, with Q3 estimated at ₹20 crore and Q4 at ₹20–25 crore.
- New customer contribution: Approximately ₹80–90 crore of current-year revenue came from newly acquired customers, indicating the commercial pipeline is converting.
- Receivables timing: The average realization cycle is 75 days, with most receivables falling due toward quarter-end and reflecting in the subsequent quarter. October was described as a very good collection period.
Aggarwal: "The guidance which we have given, we feel we are in a very comfortable position to achieve the projected numbers."
Margin Trajectory & Profitability
- EBITDA margin nearly doubled YoY: Q2 EBITDA margin reached 18.02%, up 1,256 bps YoY, with raw material costs declining to 45.15% of revenue from 49.38% a year ago. PAT surged 3.54x YoY to ₹31.03 crore, with PAT margin at 13.21%.
- H1 profitability reset: H1 FY27 EBITDA margin stood at 17.97%, up 1,254 bps YoY, with PAT up 3.29x to ₹55.47 crore. The improvement is attributed to business mix optimization and significant operating leverage.
- Q3 margin target set: Management expects Q3 FY27 margin to rise to between 19% and 20%, with the full-year blended margin exceeding 19%. The internal target is 22%, and the minimum internal FY27 goal is crossing ₹1,000 crore top line with 20% EBITDA.
- Q4 exit rate ambition: Management expects to maintain the 20%+ EBITDA level achieved in Q4 going forward into the next full year.
Aggarwal: "This is the minimum internal target which has been given to the entire team." (on crossing ₹1,000 crore top line with 20% EBITDA)
CDMO & Product Pipeline
- CDMO partnerships scaling rapidly: Commercial partnerships with major CDMO partners are on track to deliver ₹100–130 crore incremental revenue in FY27 and ₹200–220 crore over two years. CDMO contributed 26.99% of quarterly sales in Q2.
- Ibuprofen and Macrogol sachets in motion: Commercial supplies of both products are ongoing, with Ibuprofen sachet revenue accelerating from ~₹15–16 crore in H1 to an estimated ₹20 crore in Q3 and ₹20–25 crore in Q4. Management described the numbers as "very big" for both these products, along with Macrogol.
- Clarithromycin dry suspension near launch: Commercial validation is completed and the product is slated for European launch shortly. The customer has filed the variation in Europe, and batches will initiate upon approval.
- Ibuprofen site variation approved: The site variation for Ibuprofen (Viatris) has been approved and goods are being supplied. The Clarithromycin site variation is still awaited.
- R&D pipeline disclosed: 11 molecules are expected to be ready by FY28–FY29, and 2 molecules by FY29–FY30, spanning antibiotics, urology, antiprotozoals, and ulcerative colitis categories. New molecules under R&D will start registrations in early FY28 and commercialize around late FY28 or FY29.
- FY28 growth from existing pipeline: Management stated that FY28 growth will be driven by ramp-up of the existing pipeline and approved molecules, with no new molecule commercialization expected in FY28.
- Active CDMO discussions: The company is in active discussions with two additional customers beyond Viatris and Aerotex for the same products, with hopes to conclude discussions in the last quarter.
Aggarwal: "As Ind-Swift the products which we are supplying in the regulated markets we’re not competing in that molecule with the innovator so that is a big difference because whatever CDMO we’re doing for our customers in Europe we’re not competing for that molecule with our partner."
Facilities & Capacity
- Samba utilization at 70–75%: Current capacity utilization at the Samba facility is at 70–75%, and the Derabassi facility is sufficient to reach a ₹1,200 crore top line by FY28, implying significant headroom before new capacity is needed.
- Samba facility upgrade underway: A ₹45 crore upgrade to EU-GMP and PIC/S standards is on schedule, with approval expected "anytime next year." Once approved, the facility will target exports only. An ANVISA (Brazil) visit is expected probably in the last quarter of FY27.
- Warehouse relocation in progress: Land has been acquired and construction has started on a new warehouse adjacent to the 100% EOU Derabassi facility. The shift from the existing facility is expected in the next 10 to 12 months, freeing up space for additional manufacturing units.
- API sourcing concentrated: The majority of key starting materials and APIs are sourced from Synthimed, with China imports limited to only one or two molecules, reducing supply-chain risk.
Geographic & Customer Expansion
- New territory registrations underway: Registrations have been started in Peru, Mexico, Brazil, along with markets in Rwanda, Congo, Cambodia, Nigeria, Ivory Coast, and Benin. Partners have been identified and the registration process is active. Revenue growth from these new territories will flow through the export segment.
- Own-brand strategy driving mix shift: Management's stated focus is to register more own products in countries where margins are good, giving the company entire control of the product and the market. Own brands contributed 55.75% of quarterly sales and 68% of export sales.
- CDMO vs own-brand mix target: The intended ratio going forward is approximately 35% contract manufacturing and 65% own products, reflecting the strategic tilt toward higher-margin, controlled distribution.
- Competitive positioning in semi-regulated markets: Management believes it can offer a more competitive and exciting price while maintaining consistent quality, with pricing playing an important role in large, price-sensitive markets.
- Working capital advantage in own-brand business: The own-brand business mostly works on advance or LC terms, so the working capital cycle is slightly lower than the CDMO business, supporting the strategic shift.
Aggarwal: "The focus of the management is very clear: to register more and more of our products in different countries where margins are good, giving us entire control of the product and the market."
Synthimed Labs & Balance Sheet
- Synthimed stake monetization in view: IndiaRF, the majority stakeholder in Synthimed Labs, is undergoing diligence to hive off some stake. Ind-Swift holds tag-along rights and may participate in a partial liquidation if valuations are attractive. Synthimed is in talks with two leading Hyderabad-based pharma companies for acquisition.
- Management prefers patience on full exit: Management believes API business valuations are growing and prefers to wait a couple of years before liquidating the entire holding, though some portion is expected to be on the block in coming quarters.
- Balance sheet remains pristine: The company is completely net debt-free with robust cash and liquid reserves, providing capacity to fund the Samba upgrade and warehouse relocation without leverage.
- NPPA risk absent: The product portfolio does not fall under the revised NPPA price control list, so there is no impact from recent price reductions.
Aggarwal: "Since the valuations of the API business are growing, and they are in talks with two leading pharmaceutical companies based out of Hyderabad to acquire them as part of Synthimed, we feel this investment will grow. We should wait for a couple of years more before we liquidate our entire holding in this. But yes, some portion should be on the block in coming quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue growth | More than 50% YoY growth | FY27 full year |
| FY27 blended EBITDA margin | More than 19% | FY27 full year |
| Q3 FY27 EBITDA margin | 19% to 20% | Q3 FY27 |
| Internal minimum FY27 target | Cross ₹1,000 crore top line with 20% EBITDA | FY27 |
| CDMO incremental revenue | ₹100–130 crore from CDMO partnerships | FY27 |
| CDMO two-year incremental revenue | ₹200–220 crore from CDMO partnerships | FY27–FY28 |
| Samba facility EU-GMP / PIC/S approval | Approval expected | "Anytime next year" |
| ANVISA (Brazil) visit to Samba | Regulatory inspection | Probably last quarter of FY27 |
| Warehouse relocation | Shift from existing Derabassi facility | Next 10 to 12 months |
| R&D pipeline readiness | 11 molecules ready | FY28–FY29 |
| R&D pipeline readiness | 2 additional molecules ready | FY29–FY30 |
| Medium-term revenue CAGR | 20% to 25% CAGR to cross ₹1,500+ crore | By FY30 |
| Medium-term margin expansion | 200 to 300 bps EBITDA margin expansion | By FY30 |
| Q4 exit margin maintenance | Maintain 20%+ EBITDA level into next year | FY28 |
| Export vs domestic mix | Around 80% exports, 20% domestic | Going forward |
| CDMO vs own-brand mix | ~35% CDMO, ~65% own products | Going forward |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Operating Revenue | ₹234.89 cr, up 50.15% YoY and 26.22% QoQ |
| Operating EBITDA | ₹42.33 cr, up 4.95x YoY and 27.04% QoQ |
| Operating EBITDA Margin | 18.02%, expanded 1,256 bps YoY and 11 bps QoQ |
| PAT | ₹31.03 cr, up 3.54x YoY and 26.96% QoQ |
| PAT Margin | 13.21%, up 761 bps YoY |
| Raw Material Expenses | 45.15% of revenue, down from 49.38% a year ago |
| FY27 Revenue Growth Guidance | More than 50% YoY, reiterated |
| Medium-term Revenue CAGR Guidance | 20% to 25% to cross ₹1,500+ cr by FY30 |
| Medium-term EBITDA Margin Expansion Target | 200 to 300 bps expansion by FY30 |
| Export Share of Total Sales | 82.7% of total sales |
| Own Brands Share of Sales | 55.75% of quarterly sales, 69% of export sales |
| Contract Manufacturing Share of Sales | 26.99% of quarterly sales |
| CDMO Export Revenue | ~₹65 cr in Q2 FY27 |
| Own-Branding Export Revenue | ~₹125 cr in Q2 FY27 |
| Atorvastatin + Ezetimibe Revenue | ~₹58 cr in Q2 FY27, up from ~₹25 cr in Q1 FY27 |
| Ibuprofen Revenue (H1 FY27) | ~₹15 to ₹16 cr in H1 FY27 |
| Global Product Registrations | 900+ across 85 countries, backed by 2,100+ filed dossiers |
| Additional Product Registrations Expected in FY27 | 330+, with 100 to 150 already secured in H1 FY27 |
| Samba Facility Capacity Utilization | 70% to 75% |
| Derabassi Facility Capacity Utilization | 70% to 75% |
| Net Debt | Completely net debt-free with robust cash and liquid reserves |
| Trade Receivables | ~₹234 cr, up from ₹168 cr; average realization cycle 75 days |
| R&D Expenses (Q2 FY27) | ~₹8 cr |
| Equity Stake in Synthimed Labs | 7.80% |